Sensodyne Maker Haleon Leverages Eye-Level Shelf Placement To Outpace Rivals-Report
Key takeaways
- Haleon’s eye‑level shelf strategy is a win‑win for retailers and the company, nudging its U.S. market share higher amid a cost‑conscious consumer environment.
- Haleon U.S. market share 12% in August
- Haleon U.S. market share 11.4% in February
- P&G healthcare share 10.8% in July
What happened
Haleon Plc, the maker of Sensodyne, is winning U.S. shelf space at big retailers like Walmart and Target by offering lower prices, exclusive products and strong sales forecasts, boosting its market share from 11.4% in February to 12% in August.
Why it matters
Eye‑level placement drives visibility and sales; Haleon’s strategy taps into shoppers’ preference for brand names and the current inflation‑driven demand for discounted essentials, giving it a competitive edge over rivals such as P&G and Colgate‑Palmolive.
Short-term and longer-term
Short-term. Short‑term traders should watch for the rollout of eye‑level placements in Walmart and Target stores, as the initial push could lift sales of Haleon’s discounted lines and support a modest upside in the stock.
Longer-term. Over the next few months, investors should monitor how the eye‑level strategy translates into sustained market‑share gains and whether the promotion‑driven sales mix improves profitability.